News

Cytiva and Bayer to collaborate on allogeneic cell therapy manufacturing platform

July 12, 2022


  • Collaboration pairs Cytiva’s leadership in supplying end-to-end manufacturing solutions with Bayer’s strong expertise in technology and process development for complex therapeutics

  • Action demonstrates Cytiva and Bayer’s commitment to advancing and accelerating the development of cell and gene therapies and expanding their accessibility for patients


Cytiva and Bayer are teaming up to develop the first modular end-to-end manufacturing platform for allogeneic cell therapies. The companies have already kicked off the multi-year development agreement and are ramping up activities to deliver manufacturing solutions to meet the global industry’s growing demand as cell therapies advance from the laboratory to the clinic.

Jens Vogel, Senior Vice President and Global Head of Biotech, Bayer Pharmaceuticals Product Supply, says: “Through our collaboration with Cytiva, we plan to realize a uniquely flexible, modular, cell therapy manufacturing platform capable to rapidly ‘industrialize’ a broad range of cell therapies, thereby creating efficiency, standardization and economies of scale.“

“Collaborations are key to advancing and accelerating the development of novel therapeutics and ultimately helping improve patients' lives,” said Catarina Flyborg, Vice President, Cell and Gene Therapy, Cytiva. “Cytiva has a strong history as a leader in therapeutic manufacturing technologies and our collaboration with Bayer and their deep expertise in cell therapy development will enable us to create a new generation of manufacturing solutions specifically designed to meet the developing needs of allogeneic cell therapy.”

Cytiva and Bayer share the same conceptual vision for an automated and modular allogenic cell therapy manufacturing platform. Both companies believe this work will help establish new industry standards for manufacturing. Success of the Bayer-Cytiva collaboration rests with the companies’ plans to design innovative equipment and automation solutions with allogenic cell therapy in mind from the start. They plan to develop equipment and software concurrently with a focus on manufacturing speed, flexibility and a robust “plug and play” operating environment. The end goal is rapid speed to market and cost-efficient use of manufacturing infrastructure through modular design of equipment and processes.

Both parties will provide personnel, resources, and facilities to work on the joint development program. Bayer’s road map for allogeneic cell therapy manufacturing technology will be leveraged, and its development product portfolio will be among the product candidates used to support proof of concept testing of the technologies. Cytiva will utilize its equipment and consumable manufacturing expertise and technology roadmap to design the new platforms, and when complete, will make them commercially available.

News

Discover a geoinspired bioreactor : The SoftXS

October 03, 2024

Cellura developped a new kind of bioreactor based on the principle of Earth’s precession movement. Its bladeless mixing system allows homogeneous mixing with low shear forces, by respecting specific aspect...

Learn more

New modules to expand processing capabilities of the CliniMACS Prodigy® Platform: electroporation and final formulation.

June 06, 2024

The CliniMACS Prodigy® represents the next generation in automated cell processing, offering advanced integrated solutions to streamline cell processing workflows – from cell separation through cell culture to formulation of...

Learn more

New automated process to simplify the manufacturing of gene-engineered Natural Killer Cells and Clinical-grade Tumor-Reactive T cell

June 06, 2024

CAR-engineered NK cells represent a breakthrough in cancer immunotherapy, offering a host of advantages. These include multiple cytotoxicity mechanisms, a decreased risk of graft-versus-host disease (GVHD) in allogeneic scenarios, and...

Learn more

Tebubio : A complete range of solutions to optimize all your Biomanufacturing projects.

October 09, 2023

Since 1953, Tebubio facilitates Life Sciences research in France and throughout Europe. With over 80 team members across Europe, we provide researchers with a range of innovative solutions in many...

Learn more

Tebubio Laboratory : Access a personalized mini-scale mRNA production service

October 09, 2023

In response to the growing need for mRNA, Tebubio’s laboratories offer a mini-scale mRNA production service to quickly provide you with customised and optimised research grade sequences to be used...

Learn more

Microsynth France Le laboratoire de séquençage Sanger à Lyon

July 04, 2023

Learn more

Proteintechs GMP growth factors manufacturing facility, Chicago

July 04, 2023

Proteintech is a leading manufacturer of antibodies, immunoassays, proteins and Nanobodies. Overview of the Proteintech product range:  Antibodies against 13,000+ human targets. Trial size versions available.  Immunoassay kits...

Learn more

Myltenyi Biotech – New modules to expand processing capabilities of the CliniMACS Prodigy® Platform: electroporation and final formulation.

June 20, 2023

Learn more

Miltenyi Biotech – New automated process to simplify the manufacturing of gene-engineered NK Cells and Clinical-grade tumor-reactive T cell

June 20, 2023

The CliniMACS Prodigy® Tumor Reactive T (TRT) Cell Process offers a new, adaptable platform for scientists and clinicians working on tumor-infiltrating leukocyte (TIL) therapy, and can be tailored to the...

Learn more

Lumicks – Cell avidity: a new predictor of immune cell function and therapeutic success

June 20, 2023

Affinity between chimeric antigen receptor (CAR) T cells and their target have shown to be a poor predictor for T-cell function. On the contrary, cell avidity (or overall cellular binding...

Learn more

Miltenyi : New modules to expand processing capabilities of the CliniMACS Prodigy® Platform: electroporation and final formulation

August 05, 2022

The CliniMACS Prodigy represents the next generation in automated cell processing. This device offers advanced integrated solutions to streamline cell processing workflows – from cell separation through cell culture to...

Learn more

Gilson is pleased to partner with Syngoi Technologies to equip their latest GMP facility

August 04, 2022

We are pleased to announce that Gilson Connect solutions have been selected by Syngoi Technologies to enforce the traceability and repeatability of manual protocols. Syngoi Technologies is a biotechnology company...

Learn more

Gilson is pleased to partner with France Blood Transfusion Agency (EFS) Platform for Innovation in Biotherapies

August 03, 2022

Gilson is pleased to announce a new chapter of collaborating with the EFS Gene and Cell engineering unit of Bourgogne Franche Comté. The collaboration provides the EFS Development & Transfer...

Learn more

New automated process to simplify the manufacturing of gene-engineered NK Cells and Treg cells isolation

July 28, 2022

To address the variety of Treg cell applications, Miltenyi Biotec provides a broad range of tools for clinical use.

Learn more

CREAPHARM DEMONSTRATES UNPARALLELED PERFORMANCE OF -80°C NITROGEN TANK TECHNOLOGY

July 28, 2022

CREAPHARM BIOSERVICES has recently invested in -80°C nitrogen tanks to provide Biotechs and Research key players with a new solution to meet the challenges of ultra-low temperature storage.

Learn more

Videodrop, an ideal tool for the monitoring of bioproduction of Viral vectors

July 19, 2022

Today, Gene and Cell therapies are booming. However, due to the lack of solutions allowing rapid & continuous monitoring throughout the bioproduction process, Biotech’ companies are working “almost blind”. They...

Learn more

Measuring Size & concentration of nanoparticles

July 19, 2022

The Videodrop makes it possible to measure the size and concentration of biological nanoparticles like lentivirus, adenovirus or retrovirus

Learn more

Article on improving viral vector production in GEN

July 12, 2022

GEN recently interviewed our Business Development Director, Dr. Natalia Elizalde, with whom they spoke about improving the production of lentiviral vectors, vectors that VIVEbiotech develops and manufactures.

Learn more

Cytiva and Nucleus Biologics join forces to accelerate development of custom cell media for cell and gene therapies

July 07, 2022

Cytiva, a global life sciences leader, and Nucleus Biologics, LLC, The Cell Performance Company™, have signed a collaboration agreement on custom media formulation and fulfillment solutions for the cell and...

Learn more

PharmaBoardoom points out VIVEbiotech as one of the ten Spanish Biotechs to watch in 2022

July 05, 2022

PharmaBoardroom, a leading British media specialized in the health sector, has published an article in which it highlights VIVEbiotech as one of the ten Spanish biotechs to follow in 2022.

Learn more

The Analytical Scientist interviews Rakel Lopez de Maturana

June 28, 2022

The Analytical Scientist interviewed Rakel Lopez de Maturana, VIVEbiotech´s Qualified Person & Regulatory Affairs Director.

Learn more

Gurutz Linazaroso, the CEO of VIVEbiotech, in the Medicine Maker Power List 2022

June 21, 2022

The CEO of VIVEbiotech, Dr. Gurutz Linazasoro, is part of the prestigious The Medicine Maker Power List.

Learn more

Interview with Natalia Elizalde in The Medicine Maker

June 14, 2022

The Business Development Director of VIVEbiotech Dr. Natalia Elizalde was interviewed by The Medicine Maker on the challenges of lentiviral vector manufacture/use.

Learn more

Plasmid DNA manufacturing – Soon a GMP Grade unit in TEMIS Santé, Besançon – Fr

April 19, 2022

Learn more

Landau Partnership

September 22, 2021

VectorBuilder Inc., a global leader in vector design, optimization and GMP manufacturing, and Landau Biotechnology Co., a world leader in developing nonhuman primate (NHP) models for clinical research applications, have...

Learn more

Univercells Partnership

September 16, 2021

VectorBuilder – a global leader in vector design, optimization, and GMP manufacturing – has formed a worldwide strategic partnership with Univercells Technologies, a provider of novel biomanufacturing technologies for flexible...

Learn more

The MACSima™ Imaging Platform is the only complete solution for ultra high content imaging experiments.

September 13, 2021

Learn more

New automated process to simplify the manufacturing of gene-engineered hematopoietic stem cells with the CliniMACS Prodigy® HSC Engineering System

September 13, 2021

Learn more

MedXCell SA

August 25, 2021

MedXCell Science SA: MedXCell Science SA was co-founded in 2018 by the University Hospital of Montpellier (CHU of Montpellier) in France and the Swiss company MedXCell SA. It was the...

Learn more

Cryoport Systems now supporting 7 commercial therapies globally

July 27, 2021

Learn more

Polyplus-transfection initiates construction of Vectura, a new 4,000m2 facility

July 23, 2021

Learn more

Polyplus-transfection® launches FectoVIR®-AAV

July 23, 2021

Learn more

RD-Biotech: a new company from Besançon wins the « France Relance » call for projects

February 22, 2021

Following the unprecedented health crisis and its unprecedented economic impact, the Government has put in place numerous tools to support businesses.

Learn more

Covi-TRaC: arming our immune cells against SARS-COV2

September 11, 2020

A prolific period for researchers, confinement has allowed the Etablissement Français du Sang teams to generate and mature many ideas from pre-existing research. In Besançon, Marina Deschamps and Christophe Ferrand...

Learn more